ANI Pharmaceuticals IncANIP
Price$72.65Intrinsic value$129.3778% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $978.4M+59.2% YoYTTM through 30 Jun 2026
Net Income $108.3MTTM through 30 Jun 2026
Free Cash Flow $173MTTM through 30 Jun 2026

Margins

Current
Gross Margin60.6%
EBITDA Margin24.1%
Operating Margin16.4%
Net Margin11.1%

Returns

18.1%ROE
7.2%ROA
20.1%ROIC

Balance Sheet Health

Debt / Equity1.11x
Current Ratio2.91x
Net Debt$313.8M
Cash & Equivalents$360.2M

Quality Metrics

Altman Z-Score2.65
Piotroski F-Score6 / 9
FCF Margin17.7%
Rule of 4030.4
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $883.4M
Diluted EPS$4.59TTM
'19'20'21'22'23'24'25
FY2025: $3.69

Dividend

No dividend

Capital Allocation

R&D Spend$49.9M
Capex Intensity1.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.